查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401005

遲發性運動障礙治療市場，按治療類型、藥物、分佈、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Tardive Dyskinesia Therapeutics Market, By Treatment Type, By Drug, By Distribution, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 300 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022 年遲發性運動障礙治療市場規模為 23.4 億美元，2023 年至 2030 年複合CAGR為 9.1%。

遲發性運動障礙治療市場-市場動態

擴大認知到該疾病對患者健康的影響，以推動市場需求

隨著大眾和醫學專業人士認知的不斷加深，人們更加重視 TD 症狀的早期發現和治療。這鼓勵製藥公司進行包括 VMAT2 抑制劑在內的新型治療研究和開發，以滿足未滿足的醫療需求。此外，監管機構對加快 TD 藥物核准的支持強調需要為個人提供安全有效的選擇。為了提高患者的生活品質並減少這種運動障礙的影響，我們共同努力開發 TD 治療方案。

遲發性運動障礙治療市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球遲發性運動障礙治療市場在預測期內（2023-2030）每年將以 9.1% 左右的CAGR成長

由於人們越來越認知到遲發性運動障礙對患者健康的影響，遲發性運動障礙治療行業預計將以顯著的速度成長

根據治療類型細分，預計藥物療法將在 2022 年顯示最大的市場佔有率

依藥物細分，2022年丁苯那嗪為主導型

按地區分類，北美是 2022 年的主要收入來源

遲發性運動障礙治療市場區隔分析：

全球遲發性運動障礙治療市場根據治療類型、藥物、分佈和地區進行細分。

根據治療類型，市場分為兩類：藥物治療、非藥物治療。藥物療法主導市場。治療遲發性運動障礙 (TD) 的藥物治療需求量大。為了控制 TD 症狀，患者尋求有效的藥物，例如 VMAT2 抑制劑和抗精神病藥物改良藥物。製藥業致力於開發安全且量身定做的藥物，以滿足 TD 治療中對更好藥物選擇不斷成長的需求。

市場依藥物分為三類：Deutetrabenazine、Valbenazine、其他。丁苯那嗪產業在市場中佔據主導地位，並可能在預測期內保持其主導地位。 Deutetrabenazine 是一種 VMAT2 抑制劑，在遲發性運動障礙 (TD) 的治療中越來越受歡迎。它調節多巴胺水平的能力為有效治療 TD 症狀提供了希望。隨著患者和醫療保健專業人員尋求新穎的解決方案，對氘代丁苯那嗪的需求凸顯了其作為 TD 管理中有益治療選擇的潛力。

遲發性運動障礙治療市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區以及中東和非洲地區。這些區域根據開展業務的國家進一步分類。北美遲發性運動障礙 (TD) 藥物市場受到多種變數的影響。該地區有大量服用抗精神病藥物的人群，這增加了 TD 的風險。醫療保健專業人員和患者對 TD 影響的認知不斷增強，因此有必要開發適當的療法。監管部門的批准加快了新藥的上市。完善的製藥業和廣泛的醫療保健系統有助於 TD 藥物的研究、開發和傳播。需要抗精神病治療的精神疾病頻率的增加強調了解決 TD 的必要性，使北美成為旨在控制和減少 TD 症狀的新藥物的重要市場。

遲發性運動障礙治療市場-競爭格局：

遲發性運動障礙 (TD) 治療領域的主要製藥參與者包括 Neurocrine Biosciences、Teva 和 Bausch Health。這些公司處於 VMAT2 抑制劑和抗精神病藥物改良領域的前沿。治療效果、安全性和市場滲透率都是市場競爭力的重要因素。這種競爭是由臨床研究、政府批准和行銷措施決定的。利基市場參與者專注於新穎的非藥理學技術。合作與協作促進創新療法的研究與發展。競爭環境是動態的，患者人數不斷增加，意識不斷增強，尋求滿足 TD 患者未滿足的需求，並提供有效的解決方案來控制這種複雜的運動狀況。

最近的發展：

2023 年 5 月，在遲發性運動障礙意識週期間，Neurocrine Biosciences, Inc. 強調將繼續支持提高人們對遲發性運動障礙 (TD) 篩檢的盛行率、影響和相關性的認知。 TD 是一種因長期使用某些用於治療憂鬱症、精神分裂症、躁鬱症和分裂情感性疾患的精神健康藥物（抗精神病藥物）而引起的不自主運動狀況。

目錄

第1章：遲發性運動障礙治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按治療類型分類的遲發性運動障礙治療市場片段
    • 遲發性運動障礙治療市場片段（按藥物）
    • 遲發性運動障礙治療市場片段（依分佈）
    • 遲發性運動障礙治療市場片段（依國家/地區）
    • 按地區分類的遲發性運動障礙治療市場片段
  • 競爭洞察

第 3 章：遲發性運動障礙治療主要市場趨勢

  • 遲發性運動障礙治療市場促進因素
    • 市場促進因素的影響分析
  • 遲發性運動障礙治療市場限制
    • 市場限制影響分析
  • 遲發性運動障礙治療市場機會
  • 遲發性運動障礙治療市場未來趨勢

第 4 章：遲發性運動障礙治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：遲發性運動障礙治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：遲發性運動障礙治療市場格局

  • 遲發性運動障礙治療市佔率分析，2022 年
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：遲發性運動障礙治療市場 - 依治療類型

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 藥物治療
    • 非藥物療法

第 8 章：遲發性運動障礙治療市場 - 按藥物

  • 概述
    • 按藥物分類的細分市場佔有率分析
    • 丁苯那嗪
    • 纈苯那嗪
    • 其他

第 9 章：遲發性運動障礙治療市場 - 按分佈

  • 概述
    • 按分佈分類的細分市場佔有率分析
    • 醫院藥房
    • 藥局和零售藥局
    • 網路藥局

第 10 章：遲發性運動障礙治療市場 - 依地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 遲發性運動障礙治療北美主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按治療類型）
    • 北美市場規模和預測（按藥物）
    • 北美市場規模和預測（按分佈）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲遲發性運動障礙治療藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按治療類型）
    • 歐洲市場規模與預測（按藥品）
    • 歐洲市場規模與預測（按分佈）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 遲發性運動障礙治療藥物亞太地區主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按治療類型）
    • 亞太地區藥物市場規模與預測
    • 亞太地區市場規模與預測（按分佈）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 遲發性運動障礙治療藥物拉丁美洲主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按治療類型）
    • 拉丁美洲市場規模與預測（按藥品）
    • 拉丁美洲市場規模與預測（按分佈）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 遲發性運動障礙治療藥物中東和非洲主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按治療類型）
    • 中東和非洲市場規模及預測（按藥品）
    • 中東和非洲市場規模及預測（按分佈）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 遲發性運動障礙治療產業

  • 競爭儀表板
  • 公司簡介
    • Neurocrine Biosciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Companies Inc.
    • Sunovion Pharmaceuticals Inc.
    • Teikoku Pharma USA, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Neurolixis, Inc.
    • Retrophin, Inc.
    • NeuroSearch A/S
    • Abide Therapeutics, Inc.
    • Cynapsus Therapeutics Inc.
    • Ichor Medical Systems
    • Reviva Pharmaceuticals Inc.
    • Acorda Therapeutics, Inc.
    • Adamas Pharmaceuticals, Inc.

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1969

REPORT HIGHLIGHT

Tardive Dyskinesia Therapeutics Market size was valued at USD 2,340 Million in 2022, expanding at a CAGR of 9.1% from 2023 to 2030.

Tardive Dyskinesia (TD) treatments are medical procedures that try to relieve the uncontrollable and irregular movements that might occur as a consequence of long-term usage of certain antipsychotic medicines. These therapy techniques include pharmaceutical therapies such as antipsychotic adjustments or VMAT2 inhibitors, which aid in the management of TD symptoms. Non-pharmacological treatments such as behavioral counseling and deep brain stimulation can additionally be used. The purpose of TD therapies is to reduce or eliminate the disruptive motor manifestations of TD, therefore enhancing patients' general level of life and giving respite from the sometimes-upsetting symptoms of this medication-induced mobility disorder.

Tardive Dyskinesia Therapeutics Market- Market Dynamics

Increasing recognition of the condition's impact on patients' well-being to propel market demand

As public and medical professional understanding grows, there is a greater emphasis on early detection and treatment of TD symptoms. This encourages pharmaceutical companies to conduct novel therapeutic research and development, which includes VMAT2 inhibitors, to address unmet medical needs. Furthermore, regulatory authorities' support for expediting TD drug approval stresses the need to offer individuals safe and effective choices. The collaborative efforts to develop TD treatment options are driven by a desire to enhance patient's quality of life and reduce the effect of this movement disorder.

Tardive Dyskinesia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global Tardive Dyskinesia Therapeutics market is estimated to grow annually at a CAGR of around 9.1% over the forecast period (2023-2030)

The Tardive Dyskinesia Therapeutics industry is projected to grow at a significant rate due to increasing recognition of the condition's impact on patients' well-being

Based on Treatment Type segmentation, Pharmacological Therapies was predicted to show maximum market share in the year 2022

Based on Drug segmentation, Deutetrabenazine was the leading type in 2022

On the basis of region, North America was the leading revenue generator in 2022

Tardive Dyskinesia Therapeutics Market- Segmentation Analysis:

The Global Tardive Dyskinesia Therapeutics Market is segmented on the basis of Treatment Type, Drug, Distribution, and Region.

The market is divided into two categories based on Treatment Type: Pharmacological Therapies, Non-pharmacological Therapies. The Pharmacological Therapies dominates the market. Pharmacological medications are in high demand in the treatment of Tardive Dyskinesia (TD). To control TD symptoms, patients seek effective drugs such as VMAT2 inhibitors and antipsychotic modifications. The pharmaceutical industry is focused on creating safe and tailored medicines to meet the rising need for better pharmacological choices in TD therapy.

The market is divided into three categories based on Drug: Deutetrabenazine, Valbenazine, Others. The Deutetrabenazine sector dominates the market and is likely to maintain its dominance during the forecast period. Deutetrabenazine, a VMAT2 inhibitor, is becoming more popular in the treatment of Tardive Dyskinesia (TD). Its capacity to modulate dopamine levels provides promise for efficiently treating TD symptoms. The demand for deutetrabenazine highlights its potential as a beneficial treatment option in TD management as patients and healthcare professionals seek novel solutions.

Tardive Dyskinesia Therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. A variety of variables influence the market for Tardive Dyskinesia (TD) medicines in North America. The area has a large population on antipsychotic drugs, which raises the risk of TD. The growing awareness of the effects of TD among healthcare professionals and patients necessitates the development of appropriate therapies. Regulatory approval expedites the availability of novel medicines. The well-established pharmaceutical industry and extensive healthcare system assist TD medicinal research, development, and dissemination. The increased frequency of mental illnesses requiring antipsychotic treatment emphasises the need of addressing TD, making North America a critical market for novel medications targeted at controlling and reducing TD symptoms.

Tardive Dyskinesia Therapeutics Market- Competitive Landscape:

Key pharmaceutical participants in the Tardive Dyskinesia (TD) treatment landscape include Neurocrine Biosciences, Teva, and Bausch Health. These firms are at the forefront of VMAT2 inhibitors and antipsychotic modifications. Treatment effectiveness, safety profiles, and market penetration are all important factors in market competitiveness. The rivalry is shaped by clinical studies, governmental approvals, and marketing initiatives. Niche players concentrate on novel non-pharmacological techniques. Collaborations and collaborations foster innovative therapy research and development. The competitive climate is dynamic, with a rising patient population and increased awareness seeking to meet unmet requirements of TD patients and deliver effective solutions for controlling this complex movement condition.

Recent Developments:

In May 2023, During Tardive Dyskinesia Awareness Week Neurocrine Biosciences, Inc. highlighted its continuing support for raising awareness about the prevalence, impact, and relevance of screening for tardive dyskinesia (TD). TD is an involuntary movement condition caused by long-term use of certain mental health medications (antipsychotics) intended to treat depression, schizophrenia, bipolar disorder,and schizoaffective disorder.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET KEY PLAYERS

  • Neurocrine Biosciences, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Sunovion Pharmaceuticals Inc.
  • Teikoku Pharma USA, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Neurolixis, Inc.
  • Retrophin, Inc.
  • NeuroSearch A/S
  • Abide Therapeutics, Inc.
  • Cynapsus Therapeutics Inc.
  • Ichor Medical Systems
  • Reviva Pharmaceuticals Inc.
  • Acorda Therapeutics, Inc.
  • Adamas Pharmaceuticals, Inc.

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY TREATMENT TYPE

  • Pharmacological Therapies
  • Non-pharmacological Therapies

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DRUG

  • Deutetrabenazine
  • Valbenazine
  • Others

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DISTRIBUTION

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Tardive Dyskinesia Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Tardive Dyskinesia Therapeutics Market Snippet by Treatment Type
    • 2.1.2. Tardive Dyskinesia Therapeutics Market Snippet by Drug
    • 2.1.3. Tardive Dyskinesia Therapeutics Market Snippet by Distribution
    • 2.1.4. Tardive Dyskinesia Therapeutics Market Snippet by Country
    • 2.1.5. Tardive Dyskinesia Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Tardive Dyskinesia Therapeutics Key Market Trends

  • 3.1. Tardive Dyskinesia Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Tardive Dyskinesia Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Tardive Dyskinesia Therapeutics Market Opportunities
  • 3.4. Tardive Dyskinesia Therapeutics Market Future Trends

4. Tardive Dyskinesia Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Tardive Dyskinesia Therapeutics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Tardive Dyskinesia Therapeutics Market Landscape

  • 6.1. Tardive Dyskinesia Therapeutics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Tardive Dyskinesia Therapeutics Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2022 & 2030 (%)
    • 7.1.2. Pharmacological Therapies
    • 7.1.3. Non-pharmacological Therapies

8. Tardive Dyskinesia Therapeutics Market - By Drug

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug, 2022 & 2030 (%)
    • 8.1.2. Deutetrabenazine
    • 8.1.3. Valbenazine
    • 8.1.4. Others

9. Tardive Dyskinesia Therapeutics Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Drug Stores & Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Tardive Dyskinesia Therapeutics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Tardive Dyskinesia Therapeutics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Tardive Dyskinesia Therapeutics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Tardive Dyskinesia Therapeutics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Neurocrine Biosciences, Inc.
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
    • 11.2.3. Bausch Health Companies Inc.
    • 11.2.4. Sunovion Pharmaceuticals Inc.
    • 11.2.5. Teikoku Pharma USA, Inc.
    • 11.2.6. Otsuka Pharmaceutical Co., Ltd.
    • 11.2.7. Neurolixis, Inc.
    • 11.2.8. Retrophin, Inc.
    • 11.2.9. NeuroSearch A/S
    • 11.2.10. Abide Therapeutics, Inc.
    • 11.2.11. Cynapsus Therapeutics Inc.
    • 11.2.12. Ichor Medical Systems
    • 11.2.13. Reviva Pharmaceuticals Inc.
    • 11.2.14. Acorda Therapeutics, Inc.
    • 11.2.15. Adamas Pharmaceuticals, Inc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Tardive Dyskinesia Therapeutics Market: Treatment Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment Type
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Treatment Type 2018-2030 (USD Million)
  • TABLE Tardive Dyskinesia Therapeutics Market: Drug Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Drug 2018-2030 (USD Million)
  • TABLE Tardive Dyskinesia Therapeutics Market: Distribution Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Distribution 2018-2030 (USD Million)
  • TABLE Tardive Dyskinesia Therapeutics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Tardive Dyskinesia Therapeutics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE North America Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Europe Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Asia Pacific Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Latin America Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Treatment Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Tardive Dyskinesia Therapeutics Market, by Distribution, 2018-2030 (USD Million)